Clinical trial NCT05761522: Cardiovascular Effects of Norepinephrine
Official title: Cardiac Effects of Norepinephrine After the Initial Phase of Septic Shock
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Septic Shock
Keywords: ECHOCARDIOGRAPHY
CARDIAC FUNCTION
NOREPINEPHRINE
SEPTIC SHOCK
Lead sponsor: CHU de Reims
Sponsor class: OTHER
First posted: 2023-03-09
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients suffering from septic shock, after 24 hours of their diagnosis. Presenting with Mean arterial pressure (MAP)\<65 mmHg or the target MAP For whom the physician in charge decided to increase the norepinephrine dose

Brief summary: Previous studies of our team reported the improvement of myocardial contractility both on hemodynamic parameters (by transpulmonary thermodilution) and morphological (by transthoracic echocardiography: TTE), during the early phase of septic shock (during the first 4 hours management of septic shock).

However, one can wonder about the effect of NAD on myocardial cardiac ouput and contractility beyond the early phase of septic shock, more precisely beyond the first 24 hours. Indeed, while it continues to act on the "stressed" blood volume and the diastolic left ventricular perfusion by increasing the diastolic arterial pressure (DAP), it has been reported in old studies that beyond the early phase, the sensitivity of the β1-adrenergic receptors is altered due to the phenomenon of internalization of these receptors, leading to a reduction of the myocardial response to catecholamines.

The investigators can then wonder whether norepinephrine still exerts a positive effect on myocardial contractility via the increase in DAP, despite an alteration of the β1-adrenergic pathway.

To answer this question, the investigators proposed to evaluate the effects of norepinephrine by TTE on cardiac contractility after the initial phase.

Detailed description: Patients presenting with septic shock for 24 hours or more and meeting the inclusion criteria may be included.

The course of the study will be as follows:

T0: collection (as part of usual care) of clinical circulatory parameters (heart rate, systolic/diastolic/mean blood pressure) and biological parameters (arterial lactate and ScVo2) and performance of echocardiography.

Parameters collected during TTE:

* Concerning the main judgment criterion and the secondary judgment criteria:

  * Left ventricular ejection fraction (LVEF) by the Simpson Biplane method,
  * Cardiac output and cardiac index by continuity equation (measurement of left ventricular outflow chamber (mm) and sub-aortic time-velocity integral (cm/s)).
  * Tricuspid Annular Systolic Excursion (TAPSE) (mm)
  * S wave at the tricuspid ring (cm/s)
* Other parameters collected systematically:

  * Surface of the left ventricle (end-systolic and end-diastolic),
  * Global strain of the left ventricle
  * Mitral Annular Plane Systolic Excursion (MAPSE) (mm)
  * Left ventricular filling pressure (LVRP) (at the mitral annulus, E, A, e', S' waves, E/A ratio, E/e');
  * Maximum tricuspid regurgitation velocity (m/s) to estimate systolic pulmonary arterial pressure (PAPs) (mmHg)

T1: After the clinician in charge introduces or increases norepinephrine to achieve MAP ≥ 65mmHg, T1 will be when the goal of MAP ≥ 65mmHg is reached. This will be the target MAP for the management of septic shock of the patient in question according to the recommendations of learned societies.

Collection of clinical and biological circulatory parameters and performance of the TTE. The parameters collected will be the same as at T0.

Eligibility criteria: Inclusion Criteria:

* Adult patients \>18 years old
* Septic shock after 24 hours from its diagnosis
* MAP\<65 mmHg for which the physician in charge decided to increase NE

Exclusion Criteria:

* Patient under Dobutamine
* Pregnancy
* Do not resuscitation decision

Primary outcomes:
measure: The effect of the increase of Norepinephrine dose after restoring MAP on cardiac contractility evaluated by TTE : the left ventricular ejection fraction
timeFrame: through study completion, an average of 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Reims
country: France
facility: Chu Reims
Study officials:
References: